OR WAIT null SECS
April 10, 2024
Article
HBV DNA and HBsAg were not significantly associated with NAFLD in patients with treatment-naïve HBV, but age, BMI, comorbidities, and certain metabolic laboratory parameters were.
April 09, 2024
Madrigal Pharmaceuticals announced resmetirom is available in the US beginning on April 9, 2024, ushering in a new era of NASH management.
An analysis of NHANES data found no significant association between HCV infection and risk of prostate cancer, contrary to findings from previous research.
April 08, 2024
Video
Talal highlights the use of facilitated telemedicine for increasing access to HCV treatment and other areas it might expand access for underserved patient populations.
April 05, 2024
Results highlight increased safety and efficacy of curative HCV therapy among reproductive-age female patients compared with males, potentially preventing vertical infection transmission.
The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics including treatment eligibility, diagnostics, and service delivery.
April 04, 2024
Talal discusses the integration of a facilitated telemedicine approach into opioid treatment centers in New York, giving people with opioid use disorder easier access to HCV treatment.
April 03, 2024
Participants who received facilitated telemedicine initiated DAA therapy faster and had greater cure rates than those who were referred to an off-site hepatitis specialist.
April 02, 2024
Our March 2024 hepatology month in review highlights HCPLive’s coverage of the FDA approval of resmetirom for MASH/NASH and other key hepatic pipeline news.
April 01, 2024
SZN-043 showed evidence of target engagement, Wnt signal activation, and effects on liver function, supporting its advancement to a phase 1b trial in severe alcohol-associated hepatitis.